gatifloxacin has been researched along with Anthrax in 4 studies
Gatifloxacin: A fluoroquinolone antibacterial agent and DNA TOPOISOMERASE II inhibitor that is used as an ophthalmic solution for the treatment of BACTERIAL CONJUNCTIVITIS.
gatifloxacin : A monocarboxylic acid that is 4-oxo-1,4-dihydroquinoline-3-carboxylic acid which is substituted on the nitrogen by a cyclopropyl group and at positions 6, 7, and 8 by fluoro, 3-methylpiperazin-1-yl, and methoxy groups, respectively. Gatifloxacin is an antibiotic of the fourth-generation fluoroquinolone family, that like other members of that family, inhibits the bacterial topoisomerase type-II enzymes.
Anthrax: An acute infection caused by the spore-forming bacteria BACILLUS ANTHRACIS. It commonly affects hoofed animals such as sheep and goats. Infection in humans often involves the skin (cutaneous anthrax), the lungs (inhalation anthrax), or the gastrointestinal tract. Anthrax is not contagious and can be treated with antibiotics.
| Excerpt | Relevance | Reference |
|---|---|---|
| "To compare the fluoroquinolones gatifloxacin and moxifloxacin with ciprofloxacin for post-exposure prophylaxis of systemic anthrax in a BALB/c mouse model." | 3.72 | Post-exposure prophylaxis of systemic anthrax in mice and treatment with fluoroquinolones. ( Brooks, TJ; Lever, MS; Sefton, AM; Simpson, AJ; Steward, J, 2004) |
| "Gatifloxacin was administered at 6- or 8-h intervals beginning 24 h postchallenge for 21 days, and dosing was designed to produce profiles mimicking fractionated concentration-time profiles for humans." | 1.34 | Pharmacokinetics-pharmacodynamics of gatifloxacin in a lethal murine Bacillus anthracis inhalation infection model. ( Ambrose, PG; Bhavnani, SM; Craig, WA; Drusano, GL; Forrest, A; Heine, HS; Rubino, CM, 2007) |
| "Levofloxacin was bactericidal at 1 x MIC after 24 h and at 4 x MIC after 12 h, and gatifloxacin was bactericidal at 2 x MIC after 24 h and at 8 x MIC after 12 h." | 1.31 | Bactericidal activity of levofloxacin, gatifloxacin, penicillin, meropenem and rokitamycin against Bacillus anthracis clinical isolates. ( De Vecchi, E; Drago, L; Gismondo, MR; Lombardi, A; Nicola, L; Valli, M, 2002) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 4 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ambrose, PG | 1 |
| Forrest, A | 1 |
| Craig, WA | 1 |
| Rubino, CM | 1 |
| Bhavnani, SM | 1 |
| Drusano, GL | 1 |
| Heine, HS | 1 |
| Drago, L | 1 |
| De Vecchi, E | 1 |
| Lombardi, A | 1 |
| Nicola, L | 1 |
| Valli, M | 1 |
| Gismondo, MR | 1 |
| Esel, D | 1 |
| Doganay, M | 1 |
| Sumerkan, B | 1 |
| Steward, J | 1 |
| Lever, MS | 1 |
| Simpson, AJ | 1 |
| Sefton, AM | 1 |
| Brooks, TJ | 1 |
4 other studies available for gatifloxacin and Anthrax
| Article | Year |
|---|---|
Pharmacokinetics-pharmacodynamics of gatifloxacin in a lethal murine Bacillus anthracis inhalation infection model.
Topics: Air Microbiology; Animals; Anthrax; Anti-Infective Agents; Area Under Curve; Bacillus anthracis; Dis | 2007 |
Bactericidal activity of levofloxacin, gatifloxacin, penicillin, meropenem and rokitamycin against Bacillus anthracis clinical isolates.
Topics: Anthrax; Anti-Bacterial Agents; Anti-Infective Agents; Bacillus anthracis; Fluoroquinolones; Gatiflo | 2002 |
Antimicrobial susceptibilities of 40 isolates of Bacillus anthracis isolated in Turkey.
Topics: Anthrax; Anti-Bacterial Agents; Bacillus anthracis; Ciprofloxacin; Doxycycline; Drug Resistance, Bac | 2003 |
Post-exposure prophylaxis of systemic anthrax in mice and treatment with fluoroquinolones.
Topics: Animals; Anthrax; Anti-Infective Agents; Aza Compounds; Bacillus anthracis; Ciprofloxacin; Female; F | 2004 |